Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]

Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with enfortumab vedotin within its marketing authorisation for treating untreated locally advanced or metastatic urothelial cancer.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6332

Provisional Schedule

Expected publication:

21 August 2025

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors

Astellas

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Action Bladder Cancer UK

 

Fight Bladder Cancer

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Comparator companies

Merck Sharp and Dohme (pembrolizumab) (confidentiality agreement signed, participating)

 

Roche (atezolizumab) (confidentiality agreement signed, participating)

 

Advanz Pharma (methotrexate) (confidentiality agreement not signed, not participating)

 

Amgen (filgrastim, pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Baxter (doxorubicin) (confidentiality agreement not signed, not participating)

 

Chugai Pharma (lenograstim) (confidentiality agreement not signed, not participating)

 

Cipla (methotrexate) (confidentiality agreement not signed, not participating)

 

Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine) (confidentiality agreement not signed, not participating)

 

Medac GmbH (doxorubicin, methotrexate) (confidentiality agreement not signed, not participating)

 

Morningside Healthcare (methotrexate) (confidentiality agreement not signed, not participating)

 

Napp Pharmaceuticals (pegfilgrastim) (confidentiality agreement not signed, not participating)

 

Pfizer (methotrexate, doxorubicin, filgrastim) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (methotrexate) (confidentiality agreement not signed, not participating)

 

Sandoz (cisplatin, pegfilgrastim, filgrastim) (confidentiality agreement not signed, not participating)

 

Seacross Pharmaceuticals (doxorubicin) (confidentiality agreement not signed, not participating)

 

Sun Pharmaceutical (gemcitabine) (confidentiality agreement not signed, not participating)

 

Synchrony Pharma (gemcitabine) (confidentiality agreement not signed, not participating)

 

Therakind (methotrexate) (confidentiality agreement not signed, not participating)

 

Teva Pharma (lipegfilgrastim) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual